The conundrums in evaluating asthma study outcomes

A recent study is a perfect illustration of the difficulties physicians face in comparing one biological asthma drug to another, experts say. Writing in the Lancet Respiratory Medicine Phillip Korenblat and James Wedner from the Washington School of Medicine say the diversity of statistical methods applied to studies of biologics in patients with asthma, and the ...

Already a member?

Login to keep reading.

© 2021 the limbic